Galvani Bioelectronics, the developer of bioelectronic medicines launched by GlaxoSmithKline and Alphabet’s life science play Verily (formerly Google Life Sciences) in early August, will have a bioelectronic visionary on board. Moncef Slaoui, who expedited GSK investments in the field of bioelectronics, will be the chairman of the new company’s Board of Directors.
French biopharma company Pharnext has appointed René Goedkoop as its new Chief Medical Officer. He joins the neurodegenerative disease specialist from Swiss Shogu Consulting SarL.
Matthias Schroff, erstwhile CEO of Mologen, has taken over the helm of immunotherapy developer Vaximm AG. The Swiss-German company appointed him Chief Executive Officer in early September.
Swedish clinical-stage biopharmaceutical company Aprea AB has named Christian Schade President and Chief Executive Officer. Before joining Aprea, Schade was CEO of US antiviral developer Novira Therapeutics, which was acquired by Johnson & Johnson last December.
Brussels-based vaccine developer Univac has appointed a new CEO. In March, Stefano Malvolti joined Univac from Gavi, the Vaccine Alliance, where he was responsible for rolling out the vaccine development programmes of the public-private partnership.
Faron Pharmaceuticals has someone new to oversee its drug development strategy. In early May, the Turku-based clinical stage biopharma company appointed Matti Karvonen as its new Medical Director.
US- and UK-based genomics company Inivata has appointed Timothy Shannon as Chief Financial Officer. Shannon joins Inivata fom Baxano Surgical, where he held the position of CFO and treasurer.
Philippe Dro is taking over the helm of NeMoDevices AG, a Switzerland-based developer in the innovative monitoring of brain blood flow and oxygen levels. The previous CEO Michael Oberle will serve as COO in future.
Swedish rare disease expert Wilson Therapeutics AB has appointed global regulatory executive Rick Lilley as Chief Regulatory Officer.
Eduardo Bravo takes over as President of the Board of Directors of European Biopharmaceutical Enterprises (EBE). Bravo is CEO of Belgian stem cell-based drug developer TiGenix NV.